Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,952 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Watanabe T, Matsuno Y, Wakabayashi M, Maruyama D, Yamamoto K, Kubota N, Shimada K, Asagoe K, Yamaguchi M, Ando K, Ogura M, Kuroda J, Suehiro Y, Tsukasaki K, Tobinai K, Nagai H. Watanabe T, et al. Among authors: yamaguchi m. Hematol Oncol. 2024 May;42(3):e3272. doi: 10.1002/hon.3272. Hematol Oncol. 2024. PMID: 38595316 Clinical Trial.
Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T, Tobinai K, Wakabayashi M, Morishima Y, Kobayashi H, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Yoshino T, Nawano S, Terauchi T, Hotta T, Nagai H, Tsukasaki K; JCOG0203 Collaborators. Watanabe T, et al. Among authors: yamaguchi m. Lancet Haematol. 2018 Nov;5(11):e520-e531. doi: 10.1016/S2352-3026(18)30155-8. Lancet Haematol. 2018. PMID: 30389034 Clinical Trial.
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.
Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T. Shimada K, et al. Among authors: yamaguchi m. Lancet Oncol. 2020 Apr;21(4):593-602. doi: 10.1016/S1470-2045(20)30059-0. Epub 2020 Mar 11. Lancet Oncol. 2020. PMID: 32171071 Clinical Trial.
Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Miyazaki K, Suzuki R, Oguchi M, Taguchi S, Amaki J, Maeda T, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y, Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Ejima Y, Katayama N, Yamaguchi M. Miyazaki K, et al. Among authors: yamaguchi m. Hematol Oncol. 2022 Oct;40(4):667-677. doi: 10.1002/hon.2977. Epub 2022 Mar 2. Hematol Oncol. 2022. PMID: 35142384
R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203.
Watanabe T, Tobinai K, Wakabayashi M, Maruyama D, Yamamoto K, Kubota N, Shimada K, Asagoe K, Yamaguchi M, Ando K, Ogura M, Kuroda J, Suehiro Y, Matsuno Y, Tsukasaki K, Nagai H. Watanabe T, et al. Among authors: yamaguchi m. Br J Haematol. 2024 Mar;204(3):849-860. doi: 10.1111/bjh.19213. Epub 2023 Nov 23. Br J Haematol. 2024. PMID: 37996986 Clinical Trial.
Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.
Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Takeuchi K, Nawano S, Terauchi T, Hotta T. Watanabe T, et al. Among authors: yamaguchi m. J Clin Oncol. 2011 Oct 20;29(30):3990-8. doi: 10.1200/JCO.2011.34.8508. Epub 2011 Sep 19. J Clin Oncol. 2011. PMID: 21931035 Clinical Trial.
Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.
Yamaguchi M, Takata K, Yoshino T, Ishizuka N, Oguchi M, Kobayashi Y, Isobe Y, Ishizawa K, Kubota N, Itoh K, Usui N, Miyazaki K, Wasada I, Nakamura S, Matsuno Y, Oshimi K, Kinoshita T, Tsukasaki K, Tobinai K. Yamaguchi M, et al. Cancer Sci. 2014 Nov;105(11):1435-41. doi: 10.1111/cas.12526. Epub 2014 Oct 4. Cancer Sci. 2014. PMID: 25181936 Free PMC article.
Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.
Yamaguchi M, Suzuki R, Kim SJ, Ko YH, Oguchi M, Asano N, Miyazaki K, Terui Y, Kubota N, Maeda T, Kobayashi Y, Amaki J, Soejima T, Saito B, Shimoda E, Fukuhara N, Tsukamoto N, Shimada K, Choi I, Utsumi T, Ejima Y, Kim WS, Katayama N. Yamaguchi M, et al. Cancer Sci. 2018 Jun;109(6):2056-2062. doi: 10.1111/cas.13597. Epub 2018 Apr 28. Cancer Sci. 2018. PMID: 29601137 Free PMC article.
Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study - JCOG0108A.
Kinoshita T, Watanabe T, Itoh K, Yoshimura K, Tobinai K, Ogura M, Yamaguchi M, Kurosawa M, Imaizumi Y, Ota S, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Tsukasaki K, Nagai H, Shimoyama M. Kinoshita T, et al. Among authors: yamaguchi m. J Clin Exp Hematop. 2021;61(1):35-41. doi: 10.3960/jslrt.20062. J Clin Exp Hematop. 2021. PMID: 33731548 Free PMC article.
5,952 results